Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$6.64
-2.6%
$7.13
$2.32
$9.90
$359.16M2.47588,321 shs475,521 shs
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
$4.59
+5.3%
$3.35
$1.53
$4.64
$439.08M0.7317,699 shs39,718 shs
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
$8.80
+11.3%
$5.70
$2.76
$8.96
$421.87M0.4511,310 shs13,564 shs
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
$1.67
-1.2%
$1.61
$0.54
$2.45
$89.70M1.02237,856 shs81,468 shs
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
0.00%+5.08%-10.85%-1.59%-26.19%
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
0.00%+21.79%+32.68%+38.41%+98.18%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
0.00%+7.18%+50.38%+100.76%+59.80%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
0.00%+2.42%-10.58%+77.89%+208.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
1.353 of 5 stars
3.31.00.00.01.31.70.0
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
3.588 of 5 stars
3.45.00.00.04.11.70.6
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
0.8158 of 5 stars
1.33.00.00.03.30.00.6
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
2.629 of 5 stars
3.73.00.00.02.40.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
2.63
Moderate Buy$7.5714.03% Upside
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
2.80
Moderate Buy$10.40126.58% Upside
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
2.50
Moderate Buy$8.00-9.09% Downside
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
3.30
Buy$8.14387.60% Upside

Current Analyst Ratings Breakdown

Latest QNCX, NBTX, FULC, and IVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/15/2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
8/12/2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$9.00 ➝ $8.00
8/5/2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
8/5/2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Outperform$9.00
8/5/2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageStrong-Buy$9.00
7/30/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$4.00 ➝ $5.00
7/29/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$4.00 ➝ $12.00
7/17/2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
6/13/2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
6/4/2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
5/29/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$6.00 ➝ $9.00
(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$80M4.49N/AN/A$4.51 per share1.47
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
$9.95M44.13N/AN/A($1.21) per share-3.79
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
$39.18M10.77N/AN/A($1.51) per share-5.83
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
N/AN/AN/AN/A$0.69 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$9.73M-$1.22N/AN/AN/AN/A-31.05%-28.96%N/A
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
-$199.34MN/A0.00N/AN/AN/AN/AN/A9/25/2025 (Estimated)
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
-$73.73MN/A0.00N/AN/AN/AN/AN/A9/17/2025 (Estimated)
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-$56.83M-$1.09N/AN/AN/AN/A-187.49%-42.47%N/A

Latest QNCX, NBTX, FULC, and IVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-$0.28-$0.34-$0.06-$0.34N/AN/A
7/29/2025Q2 2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$0.29-$0.28+$0.01-$0.28N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/AN/AN/AN/AN/A
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
N/AN/AN/AN/AN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
N/AN/AN/AN/AN/A
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/A
24.42
24.42
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
N/A
0.92
0.92
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
N/A
1.04
1.04
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
1.45
5.00
5.00

Institutional Ownership

CompanyInstitutional Ownership
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
89.83%
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
19.06%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
38.81%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
30.75%

Insider Ownership

CompanyInsider Ownership
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
7.00%
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
32.00%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
3.45%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
16.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
10054.09 million50.31 millionOptionable
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
10095.66 million65.05 millionNot Optionable
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
10047.94 million46.29 millionNot Optionable
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
6053.71 million44.69 millionOptionable

Recent News About These Companies

Quince Therapeutics (NASDAQ:QNCX) Receives Buy Rating from D. Boral Capital
QNCX Q3 EPS Estimate Lifted by Brookline Capital Management
QNCX FY2029 EPS Increased by Brookline Capital Management
QNCX Q3 EPS Estimate Raised by Brookline Capital Management
Quince Therapeutics, Inc. (QNCX) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Fulcrum Therapeutics stock logo

Fulcrum Therapeutics NASDAQ:FULC

$6.64 -0.18 (-2.64%)
Closing price 04:00 PM Eastern
Extended Trading
$6.64 +0.00 (+0.08%)
As of 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Inventiva stock logo

Inventiva NASDAQ:IVA

$4.46 +0.10 (+2.18%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Nanobiotix stock logo

Nanobiotix NASDAQ:NBTX

$8.80 +0.89 (+11.25%)
Closing price 03:59 PM Eastern
Extended Trading
$8.75 -0.05 (-0.57%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Quince Therapeutics stock logo

Quince Therapeutics NASDAQ:QNCX

$1.67 -0.02 (-1.18%)
Closing price 04:00 PM Eastern
Extended Trading
$1.68 +0.02 (+0.90%)
As of 05:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.